期刊文献+

富马酸沃诺拉赞的合成研究 被引量:5

Synthetic study of vonoprazan fumarate
暂未订购
导出
摘要 目的开发一种合成富马酸沃诺拉赞的实用方法。提高收率,减少杂质、满足药品的质量要求。方法以5-(2-氟苯基)吡咯-3-甲醛为原料,经过N-磺酰化得到了5-(2-氟苯基)-1-(吡啶-3-磺酰基)-1H-吡咯-3-甲醛,采用甲醇重结晶除去了氯化物杂质,接着经过醛基的还原胺化、盐酸成盐除去二甲胺杂质,再中和形成沃诺拉赞,后经室温与富马酸成盐和甲醇/水(1∶1)重结晶后得到合格的富马酸沃诺拉赞。结果开发了一种实用的富马酸沃诺拉赞的合成工艺,可操作性高,杂质可控,收率提高4%,目标产物经过ESI-MS和1H NMR确认。结论研究得到了单杂<0.1%、纯度>99.5%的富马酸沃诺拉赞产品的合成工艺路线,该工艺适合工业化生产。 Objective To develop a practical synthetic process of vonoprazan fumarate with high-yield and lower impurities to meet the quality requirements.Methods By using 5-(2-fluorophenyl)pyrrole-3-carboxaldehyde as the starting material,the qualified vonoprazan fumarate was synthesized via the following steps:(1) N-sulfonylation and the chloride impurity was removed by recrystallization from MeOH;(2) the aldehyde was converted to amine by reductive amination,followed by forming the vonoprazan chloride to remove the dimethylamino impurity;(3) vonoprazan free base was obtained by neutralization and then converted to fumarate at room temperature and finally recrystallized from MeOH/H_2O(1∶1).Results An impurity controllable synthetic process was developed with a 4% total yield improving.The final product was confirmed by ESI-MS and ~1H NMR.Conclusion The synthetic process with single impurity less than 0.1% and purity above 99.5% was obtained and suitable for scale production of vonoprazan fumarate.
出处 《国际药学研究杂志》 CSCD 北大核心 2017年第9期890-893,共4页 Journal of International Pharmaceutical Research
关键词 质子泵抑制剂 富马酸沃诺拉赞 合成研究 protonpump inhibitor vonoprazan fumarate synthesis study
  • 相关文献

参考文献2

二级参考文献11

  • 1刘志敏.胃酸分泌抑制剂治疗溃疡病近况[J].医药导报,1993,12(4):171-173. 被引量:3
  • 2孟繁浩,张守芳,高文方,阵光文.2-酰基吡咯的合成及Vilsmeier反应的研究[J].精细化工,1996,13(1):16-18. 被引量:2
  • 3Wallmark B, Briving C, Fryklund J, et al. Inhibition of gastric H, K-ATPase and acid secretion by SCH 28080,asubstituted pyridy 1 (1,2a)imidazole[J]. J Biol Chem, 1987, 262:2 077-2 084.
  • 4Scott C K, Sundell E, Castro villy L. Studies on the mechanism of action of the gastric microsomal (H+, K)-ATPase inhibitors SCH 32651 and SCH 28080[J]. Biochem Pharmacol, 1987, 36: 97-104.
  • 5Shin J M, Cho Y M, Sachs G. Chemistry of covalent inhibition of the gastric(H,K+)-ATPase by proton pump inhibitors[J]. J Am Chem Soc, 2004, 126:7 800-7 811.
  • 6Schubert M L, Peura D A. Control of gastric acid secretion in health and disease[J]. Gastroenterology, 2008, 134:1 842-1 860.
  • 7Garnock-Jones KP. Vonoprazan: first global approval [J]. Drugs, 2015, 75 (4) :439--443.
  • 8Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan(TAK-438) to the gastric H*, K+- ATPase [ J]. Aliment Pharmaeol Ther, 2015, 42 ( 11-12) : 1315--1326.
  • 9Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK- 438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects [J]. Aliment Pharmaeol Ther, 2015, 41 (7) : 636--648.
  • 10池本朋己,水船秀哉,长田敏明,等.制备吡咯化合物的方法:中国,104211618[P].2014-12-17.

共引文献11

同被引文献28

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部